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Despite intensified salvage treatments, children withrelapsed/refractory acute myeloid leukemia (AML) have poorsurvival. We evaluated gemtuzumab ozogamicin (CD33-targeted
drug) used on a compassionate basis in patients diagnosed from 1995
until 2014 within Acute Myeloid Leukemia Berlin-Frankfurt-Münster
studies, and identified 76 patients (<18 years) with highly-advanced and
pre-treated AML  [refractory de novo acute myeloid leukemia (n=10), 
de novo AML refractory to relapse (1st early: n=41; 1st late: n=10; 2nd or
more: n=10), and secondary AML (n=5)]. At doses of 2.5-10 mg/m2, gem-
tuzumab ozogamicin was administered in 1-4 cycles as single agent
(47%), combined with cytarabine (47%), or others (6%). Most common
grade 3/4 adverse events were infections or febrile neutropenia (78% of
severe adverse events), infusion-related immunological reactions (6%),
and gastrointestinal symptoms (5%). Three patients experienced veno-
occlusive disease (one fatal due to exacerbation of a pre-existing car-
diomyopathy). Sixty-four percent received subsequent hematopoietic
stem cell transplantation. Probability of 4-year overall survival was
18±5% in all, 27±7% in patients with and 0% in patients without
hematopoietic stem cell transplantation (P<0.0001). Administration of
gemtuzumab ozogamicin on a patient-specific, compassionate use basis
was frequently considered in our study group and proved to be effective
for bridging children with very advanced AML to hematopoietic stem
cell transplantation. Uniform prospective studies for these patients are
urgently needed.    
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ABSTRACT
Introduction
Treatment of acute myeloid leukemia (AML) in children has improved remark-
ably during the past decades; however, pediatric patients with relapsed and refrac-
tory AML still have poor outcomes.1-6 These outcomes rely on disease-dependent
characteristics, such as initial cytogenetics, in addition to response-to-therapy-relat-
ed factors like the interval between initial diagnosis and relapse.7-10 Considering
poor outcome and high toxicity of current salvage therapies, new targeted molecu-
lar treatments are needed.11-13 
Gemtuzumab ozogamicin (GO) is an immunotoxin consisting of a potent
humanized monoclonal antibody against CD33, and targets CD33 positive cells
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which are present in approximately 80-90% of childhood
AML.14,15 Although CD33 has been considered as a specific
marker for hematopoietic cells of the myeloid lineage for
a long time, this surface marker is also found to be
expressed in hepatocytes which may potentially cause
some off-target effects.16
Treatment with GO in different settings has previously
been shown to be of value in pediatric AML. The first
international experience of treatment with GO as
monotherapy for compassionate use for children with
relapsed or refractory AML (n=15) in 2003 suggested the
efficacy of this treatment with doses of 4-9 mg/m2 in up to
3 cycles.17 A later phase II study showed that treatment
with two doses of 7.5 mg/m2 GO with 14-day intervals in
children with advanced AML (refractory, first refractory
relapse or ≥second relapse) led to significantly higher sur-
vival in patients who received GO compared to patients
who did not receive this treatment (3-year probability of
overall survival: 27% vs. 0%, respectively; P=0.001).18 In
addition to monotherapy, a good response rate was also
achieved when GO was administered in combination
with cytarabine in 17 children with relapsed or refractory
AML [overall complete remission (CR) rate: 53%].19
Currently there are at least 9 active clinical trials world-
wide investigating the effect of GO in AML (de novo,
relapsed, or refractory). One of these trials only recruits
children and 4 are recruiting children in addition to adults
or elderly patients (Online Supplementary Table S1). Of
interest, there is one active clinical trial which studies
treatment with GO in compassionate use in refractory or
relapsed AML (clinicaltrials.gov identifier: 02312037), which
recruits children, adult, and elderly groups of patients.20
Considering the above-mentioned challenges in the
treatment of relapsed and refractory pediatric AML, the
infrequency of new treatment options, and in addition,
the restricted accessibility of GO, we aimed to identify
patients treated with GO as compassionate use in the
AML-Berlin-Frankfurt-Münster (AML-BFM) study group
and to evaluate the efficacy and safety in this heavily pre-
treated group of patients. 
Methods
Patients
Between January 1995 and March 2014, 2601 children with ini-
tial diagnosis at the age of ≤18 years were documented within the
AML-BFM study group. Patients or guardians provided written
informed consent. The current analysis was performed in accor-
dance with the Declaration of Helsinki and was approved by the
local ethics committee. The AML-BFM Study Group centrally
reviewed the diagnosis of initial disease or relapse via bone mar-
row morphology and flow cytometry. All patients’ records were
evaluated retrospectively for the use of GO. Medical reports of the
patients treated with GO were reviewed retrospectively for eval-
uation of treatment outcomes and adverse events (AE). 
Treatment protocols
Before administration of GO, patients were treated based on
randomized, phase III studies AML-BFM 93, 98, and 2004 running
in 75 centers in Germany, Austria, Switzerland, and the Czech
Republic. These treatment protocols have been previously
described in detail.21-23 All studies were performed after the
approval by national ethics committees and institutional review
boards. The AML-BFM 93 recruited patients between January
1993 and June 1998, and was followed by AML-BFM 98 which
was opened in July 1998 and closed in June 2003. Between July
2003 and April 2004, the AML-BFM 98 Interim Study continued
treatment of recruited patients with the best arm of the AML-BFM
98 trial. The AML-BFM 04 study was opened in April 2004 and
randomization continued until April 2010. After April 2010 and
until February 2014, the AML-BFM 2004 Interim Study continued
treatment of patients with the experimental arm of the AML-BFM
2004 trial. Second-line treatment of patients included the Relapse
AML 2001/01 trial24 which recruited patients from November 2001
to April 2009 and the International Registry Relapsed AML 2009.7
Patients included in the current cohort had received intensive treat-
ment and/or HSCT before administration of GO. Considering the
first treatment after initial diagnosis as first attempt, and each fol-
lowing treatment block or HSCT as further individual attempts,
most of the patients (n=35, 46%) in the total cohort received GO
as their 3rd treatment attempt (Online Supplementary Figure S1).
Treatment with GO
During the period of analysis, 217 patients with non-response
(NR) and 654 patients with at least one event of relapse were doc-
umented (Online Supplementary Figure S2). Within these patient
records, 98 (from 39 different centers) were found with a positive
history of GO treatment, 10 of which were included in the previ-
ously mentioned phase II trial18 and who were, thus, excluded
from the current study. The remaining 88 patients received GO on
a compassionate use basis, after failure of their first- and/or sec-
ond-line treatments and/or when the general condition of patients
was so poor that further intensive chemotherapy was not possi-
ble. Treatment with GO in these patients was recommended by
the centralized study co-ordination office, and finally prescribed
by the patients’ treating physicians at each local center. Patients or
guardians provided written informed consent. GO was provided
by International Pharmacy (San Francisco, CA, USA) through
Clinigen (London, UK) and, for some patients, by Pfizer (New
York, NY, USA) on a compassionate use program. From these 88
patients, 76 had sufficient data to evaluate the outcomes of GO
use and were included in this study (Online Supplementary Figure
S2). Three of the 76 patients have been previously reported.17
Grading of toxicity and adverse events was carried out using the
NCI Common Terminology Criteria for Adverse Events (CTCAE),
version 4.03, revised in June 14, 2010.25 Records concerning the
safety evaluation of GO were not available for 5 patients (Online
Supplementary Figure S2). 
Definitions and statistical analysis
Bone marrow (BM) relapse was defined by presence of >5% of
leukemic cells in the BM. Relapse events during the first 12
months from diagnosis of AML were considered as early relapse.3
Complete remission (CR) was defined with the presence of less
than 5% blasts in morphological examination of BM in addition to
satisfactory hematologic recovery (absolute neutrophil count > 1.0
x109/L, platelet count >80x109/L in the peripheral blood).21
Reaching CR without complete blood recovery was defined as
incomplete CR (CRi).21 Response to GO was evaluated in patients
who received HSCT after treatment with GO and was defined as
CR plus CRi (CR/CRi). Persistence of ≥5% BM leukemic blasts
was categorized as NR.
Overall survival (OS) after GO was defined as the time from the
first dose until death by any cause or until the last follow up.
Probability of OS was calculated according to Kaplan-Meier and
compared by log-rank test. P<0.05 was considered significant.
Data were analyzed using SAS (Statistical Analysis System
Version 9.4; SAS Institute, Cary, NC, USA).  Data acquisition was
stopped on 1st June 2017. 
Gemtuzumab in pediatric acute myeloid leukemia
haematologica | 2019; 104(1) 121
Results
Patients’ characteristics and treatment with GO 
The majority of patients were initially diagnosed with
AML with the French-American-British (FAB) classifica-
tion of M4 (without atypical eosinophils) or M5 (n=29,
39%) and 13 (17%) patients had white blood cell (WBC)
counts higher than 100x109/L at the time of their diagno-
sis. In total, 67 (88%) patients had high-risk AML as
defined by morphology, cytogenetics and response to
treatment, retrospectively (Table 1). Most of the patients
(n=43, 56%) had been previously treated with liposomal
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Table 1. Patients’ characteristics at initial diagnosis.
Feature n %
Total number of patients 76 100
Age, years 
Median (range) 9.3 (1 months - 17 years) 
Categories
0-2 15 20
3-10 26 34
11-18 35 46
Sex
Female 33 43
Male 43 57
FAB Classification
M0 6 8
M1/M2 25 33
M3 1 1
M4Eo-/M5 29 39
M6 1 1
M7 7 9
AML-not classified 7 9
WBC count at diagnosis
Median x109/L(range) 14.8 (0.39 - 324)
Patients with WBC ≤100x109/L 62 82
Patients with WBC >100x109/L 13 17
No data 1 1
Previous treatments
Pre-treatment with FLA/G 12 16
Pre-treatment with FLA/G+DX (+/- FLA/G)a 43 56
Pre-treatment without FLA/G+DX or FLA/G 21 28
HSCT prior to GO treatment
Yes 14 18
No 62 82
Disease status prior to GO
Refractory de novo AMLb 10 13
De novo AML- refractory to 1st early relapsec 41 54
De novo AML-refractory to 1st late relapsec 10 13
De novo AML- refractory to 2nd relapsec 8 11
De novo AML-refractory to 3rd relapsec 2 3
Secondary AML- refractory to 1st/2nd relapsec 5 6
Risk groupd
Standard risk 9 12
High risk 67 88
n: number; FAB classification: French-American-British classification; M4Eo-: AML M4 subtype without the presence of atypical eosinophils; AML: acute myeloid leukemia; HSCT:
hematopoietic stem cell transplantation; FLA/G: fludarabine, cytarabine with or without granulocyte colony stimulating factor; DX: liposomal daunorubicin; GO: gemtuzumab
ozogamicin; WBC: white blood cell. aSome of the patients in this category received FLA/G in addition to FLA/G+DX. bGO was administered after failure of first-line treatment(s).
cGO was administered after failure of treatment for the relapse episode. dStandard risk indicates FAB M1/2 with Auer rods, FAB M4 with atypical eosinophils (M4Eo), FAB M3
and/or favorable cytogenetics, such as t(8;21) and/or AML1-ETO, t(15;17), and/or PML-RARA and inv(16) or t(16;16) and/or CBFB/MYH1, if there was no persistence of BM blasts
(≥5%) on day 15. FLT3-ITD positivity was not considered. All others were classified as high-risk patients.
daunorubicin and fludarabine in addition to cytarabine
with or without granulocyte colony stimulating factor
(FLA/G+DX). Fourteen (18%) patients received HSCT
prior to treatment with GO (Table 1). GO was adminis-
tered after failure of treatment attempts at different time
points of therapy and most (n=41, 54%) of the patients
were treated with GO after failure of treatment(s) for first-
early relapse of de novo AML (de novo AML, refractory to
first early relapse) (Table 1). GO was equally prescribed as
either monotherapy (n=36, 47%) or in combination with
cytarabine (n=36, 47%), and the remaining patients (n=4,
6%) received GO in combination with other agents (Table
2). Most patients (n=48, 63%) received one cycle of GO as
monotherapy or combination therapy (Table 2). GO was
frequently administered at doses of 3 mg/m² or lower
(n=37, 49%) (Table 2) and most of these patients received
Gemtuzumab in pediatric acute myeloid leukemia
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Table 2. Details and outcomes of treatment with gemtuzumab ozogamicin.
Disease status Refractory De novo AML, De novo AML, De novo AML, Total
prior to GO de novo AML refractory to 1st refractory to 1st refractory to ≥2nd cohort
early relapse late relapse relapses/secondary AML
Number (%) 10 (100) 41 (100) 10 (100) 15 (100) 76 (100)
Age, median (range) 
at initial diagnosis (years) 10 7.5 12.6 10.3 9.3
(2 months -14) (4 months -17) (8 months - 16) (1 month -16) (1 month -17)
at treatment with GO (years) 10.3 8.1 15.7 12.2 10.4
(7 months -15) (1 - 18) (2 - 20) (9 months -16) (7 months - 20)
Treatment with GO
monotherapy 4 (40) 17 (41) 3 (30) 12 (80) 36 (47)
GO + cytarabine 6 (60) 20 (49) 7 (70) 3 (20) 36 (47)
other 0 (0) 4 (10) 0 (0) 0 (0) 4 (6)
Number of cycles
one 6 (60) 27 (66) 7 (70) 8 (53) 48 (63)
two 4 (40) 10 (24) 3 (30) 7 (47) 24 (32)
three 0 (0) 3 (8) 0 (0) 0 (0) 3 (4)
four 0 (0) 1 (2) 0 (0) 0 (0) 1 (1)
GO dosage at the first cycle
≤ 3 mg/m² 6 (60) 20 (49) 7 (70) 4 (27) 37 (49)
3.1 – 5.4 mg/m² 2 (20) 5 (12) 0 (0) 1 (7) 8 (10)
5.5 - 7.5 mg/m² 2 (20) 10 (24) 1 (10) 8 (53) 21 (28)
> 7.5 mg/m² 0 (0) 4 (10) 2 (20) 2 (13) 8 (10)
n.d. 0 (0) 2 (5) 0 (0) 0 (0) 2 (3)
HSCT after GO treatment 
Yes 8 (80) 28 (68) 8 (80) 5 (33) 49 (64)
1st HSCT 8 27 8 3 46 
2nd HSCT 0 1 0 2 3
No 2 (20) 13 (32) 2 (20) 10 (67) 27 (36)
Extra treatment prior to HSCTa
Chemotherapy 2 (25) 9 (32) 2 (25) 1 (20) 14 (28)
No-treatment 6 (75) 16 (57) 5 (63) 2 (40) 29 (60)
Other 0 (0) 1 (4) 1 (12) 1 (20) 3 (6)
n.d. 0 (0) 2 (7) 0 (0) 1 (20) 3 (6)
Bone marrow response prior to HSCTa
CR 2 (25) 1 (4) 1 (12) 1 (20) 5 (10)
CRi 2 (25) 13 (46) 2 (25) 3 (60) 20 (41)
NR 3 (38) 12 (43) 3 (37) 1 (20) 19 (39)
n.d. 1 (12) 2 (7) 2 (26) 0 (0) 5 (10)
Patient status
Alive 3 (30) 5 (12) 5 (50) 2 (13) 15 (20)
Deceased 7 (70) 36 (88) 5 (50) 13 (87) 61 (80)
GO: gemtuzumab ozogamicin; n.d.: no data; HSCT: hematopoietic stem cell transplantation; CR: complete remission; CRi: complete remission with incomplete hematologic recov-
ery; NR: non-response. aPercentages in this category were calculated only for patients who received HSCT.
GO in combination with cytarabine or other agents fol-
lowing the failure of treatment after first early relapse
(n=20 of 37, 54%) (data not shown). When GO was admin-
istered as monotherapy, higher doses were used (Figure 1).
Safety and toxicities
Among 71 patients who were evaluated for AEs during
the first cycle of treatment, most common AEs were grade
3/4 infections or febrile neutropenia (61 events in 49
patients, 69%) (Table 3). Two patients suffered from sep-
sis and were successfully managed with supportive and
anti-bacterial therapy. Gastrointestinal (GI) symptoms (11
grade 1/2 events in 11 patients and 4 grade 3/4 events in 4
patients) and immunologic reactions such as infusion-
related fever, chills, or hypotension (7 grade-1/2 events in
7 patients and 5 grade 3/4 events in 5 patients) were most
frequently observed after infections. Due to interference
with other treatments, GI events could not be assigned to
GO with certainty.
Among grade 3 and 4 AEs, febrile neutropenia was most
frequently observed in both groups of patients with
monotherapy and combination therapy as well as in all
different groups of patients independently of their previ-
ous treatments (FLA/G or FLA/G+DX or patients with
HSCT prior to GO) (data not shown). The majority (4 of 5)
of patients with severe infusion-related immunological
reactions to GO treatment, had previously received GO as
monotherapy with higher doses compared to patients
with combination therapy (data not shown). 
Veno-occlusive disease (VOD) occurred in 3 patients
who received GO as monotherapy (one cycle) at doses of
6, 7.5, and 9 mg/m2. All 3 patients had FLA/G+DX as treat-
ment before GO, and received defibrotide as prophylaxis
against VOD. Two of these patients were treated with
HSCT prior to treatment with GO (6 or 7.5 mg/m2). The
patient treated with 6 mg/m2 GO had a previous history
of VOD and developed a GO-related VOD before the
scheduled HSCT that was successfully treated without
late effects or events. The other 2 patients could not
receive HSCT after treatment with GO and both died.
Cause of death in one of them was disease (leukemic) pro-
gression, and the other patient experienced exacerbation
of a pre-existing cardiomyopathy leading to death 24 days
after GO treatment. In addition, treatment with GO
resulted in exacerbation of previous symptoms in 2
patients (pulmonary aspergillosis infection or gastroin-
testinal toxicity) and, due to overlap with other treatments
and HSCT, the consequences of these AEs could not be
exclusively correlated to GO (Table 3). Similarly, the con-
sequences of different AEs in one patient with GO-related
cytokine syndrome and pre-existing respiratory distress
could not be distinguished from each other (Table 3). The
respiratory distress in this patient was related to an apla-
sia-associated pneumonia which was caused by teatments
before GO.
Outcome
With a median follow up time of 4.3 years (range: 1-5
years), the probability of 4-year OS after treatment with
N. Niktoreh et al.
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Figure 1. Gemtuzumab ozogamicin (GO) dosage. GO dosage based on admin-
istration with cytarabine or other agents. AML: acute myeloid leukemia; n.d. : no
data.
Figure 2. Survival after gemtuzumab ozogamicin (GO). (A) 4-year probability of
overall survival (OS) in all patients. (B) 4-year probability of OS in different dis-
ease statuses. (C) 4-year probability of OS based on administration of
hematopoietic stem cell transplantation (HSCT). pOS: probablity of OS; n: num-
ber of patients; AML: acute myeloid leukemia; SE: Standard Error. 
A
B
C
GO was 18±5% in the total cohort (Figure 2A). A compar-
ison of disease status prior to treatment with GO between
patient groups showed that patients who received GO
after de novo AML refractory to first late relapse had a
probability of 4-year OS of 48±16%; this is significantly
higher than in patients with de novo AML refractory to first
early relapse (probability of 4-year OS: 12±5%; P=0.03)
and patients with de novo AML refractory to second or
more relapses/secondary AML (probability of 4-year OS:
10±9%; P=0.02) (Figure 2B). Based on the current retro-
spective analysis, factors such as number of cycles and
administration of GO as monotherapy or in combination
with cytarabine or other agents did not have any signifi-
cant influence on survival (Online Supplementary Figure
S3A-C).
In the total cohort of patients, 27 (36%) did not receive
HSCT after treatment with GO (Table 2) and none of
these patients survived (Figure 2C). Of note, most (10 of
15, 67%) patients with de novo AML refractory to second
or more relapses/secondary AML, did not receive an
HSCT after GO treatment; this is higher than in other
groups of patients (Table 2).
From the total group of 76 patients, 49 (64%) received
HSCT after GO treatment and their probability of 4-year
OS was 27±7%. Thirty (61%) patients with HSCT received
GO in combination with cytarabine (data not shown). HSCT
after GO was the first HSCT for most of the patients (n=46,
94%), and mean time to transplantation after GO treatment
was 41±30 days (range 11-135 days). The probability of 4-
year OS in patients who received HSCT early during the
first three weeks after GO treatment was 9±9% and
patients who received HSCT between three and six weeks
after GO administration had a 4-year OS of 40±11%
(P=0.06) (Online Supplementary Figure S3D).  
Previous treatment with or without FLA/G+DX before
GO administration had no influence on the percentage of
HSCT achieved after treatment with GO (FLA/G+DX
group: 29 of 43, 67%; no FLA/G+DX or FL/A group: 14 of
21, 67%) (data not shown). However, among transplanted
patients, fewer patients with previous FLA/G+DX (7 of
29, 24%) survived compared to the patients without
FLA/G+DX or FL/A (6 of 14, 42%) (data not shown). In
addition, one patient with de novo AML-M3 refractory to
first late relapse is alive after treatment with GO followed
by additional chemotherapy and HSCT. 
Among 49 patients with subsequent HSCT, 25 (51%)
reached CR/CRi before HSCT (Table 2). Out of 19
patients with no response to GO before HSCT, 8 (42%)
received additional chemotherapy before HSCT and 3 of
them survived. The remaining 11 (58%) patients with no
response, received HSCT with no further chemotherapy
and 2 of these patients survived (data not shown).
Discussion
The major goal in the treatment of relapsed/refractory
pediatric AML is to develop new therapeutic options to
achieve complete remission and proceed to HSCT there-
after.26 Considering the previous history of intensive
chemotherapy and/or previous HSCT in these patients,
novel treatment options should be efficient, but must also
have acceptable toxicity profiles. However, the introduc-
tion of new drugs is challenging. Due to increasing regula-
tory challenges and requirements, as well as limited acces-
sibility of drugs such as GO, it is more and more time con-
suming to open phase III trials. Hence a follow-up trial,
that has been planned since 2009 after the end of the
phase II trial,18 was not opened until September 2016 and
recruited the first patient in August 2017 (EudraCT n.:
2010-018980-41). 
In the current analysis, we have evaluated the use of GO
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Table 3. Non-hematologic adverse events in 71 patients after the first treatment cycle with gemtuzumab ozogamicin.
AE severity/ All gradesa Grades 1/2 Grades 3 and 4
consequence Total AEs, reversible             reversible prolonged             progressive fatal n.a.
reversible
All outcomes
n (%) AEs Patients AEs Patients AEs Patients AEs Patients AEs Patients AEs Patients
Gastrointestinal 15 (15) 11 11 4 4 0 0 0 0 0 0 0 0
Pain 4 (4) 1 1 3 3 0 0 0 0 0 0 0 0
Infection or fever 61 (60) 0 0 58 46 2 2 1b 1 0 0 0 0
in neutropenia
VOD 3 (3) 0 0 1 1 1 1 0 0 1c 1 0 0
Infusion-related 12 (12) 7 7 4 4 0 0 0 0 0 0 1d 1
immunological reactions
Exacerbation of the 2 (2) 0 0 0 0 0 0 0 0 0 0 2e 2
previous conditions
Constitutional symptoms 2 (2) 2 2 0 0 0 0 0 0 0 0 0 0
Metabolic/laboratory 2 (2) 2 2 0 0 0 0 0 0 0 0 0 0
Total, nf (%) 101 (100) 23 (23) 70 (69) 3 (3)          1 (1)     1 (1)                         3 (3)
AE: adverse events; n: number; n.a.: not applicable; VOD: veno-occlusive disease. aGrading of toxicity and adverse events based on the NCI Common Terminology Criteria for
Adverse Events (CTCAE), version 4.03, revised June 14, 2010. bProgressive fever partly resulted from limiting its treatment due to joint decision to terminate the “active” therapy
of the patient. cGO-related VOD led to exacerbation of a pre-existing cardiomyopathy causing death 24 days after the treatment with GO. dTreatment with GO resulted in occur-
rence of cytokine syndrome in a patient with pre-existing respiratory distress due to aplasia-associated pneumonia. Following a decrease in level of consciousness, this patient
died five days after occurrence of the cytokine syndrome. eTreatment with GO resulted in worsening of previously present pulmonary aspergillosis infection or in worsening of
previously observed gastrointestinal toxicity. fAll adverse events in 71 patients were evaluated.
on a compassionate use basis in a cohort of children with
refractory de novo AML and de novo or secondary AML
refractory to relapse therapy. The use of GO in heavily
pre-treated patients translated into a substantial rate of
subsequent HSCT of 64% and a probability of 4-year OS
of 27% in these patients. The safety profile in our cohort
was tolerable, which may allow the use of GO in patients
with a history of intensive therapies. 
We have identified 88 and analyzed 76 children with
relapsed/refractory AML who were treated with GO on a
compassionate use basis. Compared to other studies
which evaluated the outcomes of treatment with GO in
patients with relapsed/refractory AML either on a com-
passionate use basis (Zwaan et al., 15 patients;17 Brethon et
al., 17 patients)19 or with other treatment strategies (29
patients with relapsed/refractory AML in an open-label,
dose-escalation study;27 45 children with relapsed/refrac-
tory AML included in the AAML00P2 randomized clinical
trial;28 30 children with advanced relapsed/refractory AML
in an investigator-initiated phase II study)18 the current
cohort contains the largest number of patients. 
With GO doses of 2.5-10 mg/m2, 64% of the patients
included in our cohort subsequently received HSCT, and
51% of these patients reached complete remission with or
without hematologic recovery before receiving HSCT. In
2005, Arceci et al. studied the effect of treatment with GO
as a single agent with doses of 6-9 mg/m2 (2 doses, 2-week
intervals) in 10 children with refractory AML and 19 with
relapsed AML.27 They defined response to GO as achiev-
ing CR (presence of ≤5% blasts in BM with full hemato-
logic recovery: hemoglobin level ≥9 g/dL, absolute neu-
trophil count ≥1.5x109/L, and platelet count ≥100x109/L)
and showed a response rate of 30% and 26% in patients
with refractory and relapsed AML, respectively, accompa-
nied by acceptable safety profiles.27 In addition, in a study
by Brethon et al., in 2006, outcome of monotherapy with
GO on a compassionate basis (single dose: 3-9 mg/m2) in
children with refractory (3 patients) and relapsed (9
patients) AML was investigated.29 The results of this study
showed a CR (plus CR without hematologic recovery)
rate of 25% in patients with subsequent HSCT.29 Of note,
a subsequent study by the same group in 2008 showed
that the response rate was higher (overall CR: 53%) when
GO was administered in combination with cytarabine in
children with relapsed or refractory AML.19 We could not
confirm the benefit of this combination treatment in our
cohort since combination of GO with cytarabine alone, or
with cytarabine along with other agents or combination
of GO with vincristine had no survival advantage com-
pared to single agent therapy. 
Myelosuppression accompanied by fever was the most
common GO-related AE in our patients (49 events in 58%
of patients) (data not shown) that appeared to be independ-
ent of GO dosage, combination/monotherapy, previous
treatments, or disease status prior to GO. Rates of myelo-
suppression by GO were previously reported at a range of
25-100% in different studies.19,28,29
In our cohort, the rate of VOD after treatment with GO
was 4%. Frequency of VOD related to monotherapy or
combination GO therapy in children has been previously
reported with a wide range across different studies from
no events29,30 to 10-24%.27,28,31 However, taken together, the
results of previous studies show that the incidence of
VOD is directly associated with the absolute single dose
of GO, which is higher when it is administered as
monotherapy.32 These findings are in accordance with the
results of the current cohort. Considering the suggested
increased risk of VOD in cases of monotherapy with GO,
and the lack of a survival advantage between monothera-
py and combination therapy in our current cohort, admin-
istration of GO in combination with other agents, such as
cytarabine, may be useful to prevent this complication.
It should be noted that the current analysis is limited by
its retrospective study design and especially by the lack of
a control group. These restrictions have hindered our
efforts to identify the contribution of compassionate treat-
ment with GO as a single factor to the outcomes of the
current study.
In conclusion, we have shown in a large cohort of
patients with relapsed/refractory de novo and secondary
AML, with a history of very intensive treatments includ-
ing chemotherapy and/or HSCT, that administration of
GO on a compassionate use basis was frequently consid-
ered. The study provides evidence that GO can enable a
subsequent blast reduction that allowed HSCT in these
patients and survival without imposing major adverse
events. Since addition of GO showed the potential to
improve treatment outcomes in the current cohort of
patients with relapsed/refractory pediatric AML, the role
of GO in these patient groups should ideally be proven in
large prospective randomized clinical trials. Therefore, we
have now included GO as front-line treatment of
relapsed/refractory pediatric AML in our ongoing phase III
multicenter clinical trial (EudraCT number: 2010-018980-
41, recruiting since August 2017). 
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